190 related articles for article (PubMed ID: 37246765)
1. Ex vivo to in vivo model of malignant peripheral nerve sheath tumors for precision oncology.
Larsson AT; Bhatia H; Calizo A; Pollard K; Zhang X; Conniff E; Tibbitts JF; Rono E; Cummins K; Osum SH; Williams KB; Crampton AL; Jubenville T; Schefer D; Yang K; Lyu Y; Pino JC; Bade J; Gross JM; Lisok A; Dehner CA; Chrisinger JSA; He K; Gosline SJC; Pratilas CA; Largaespada DA; Wood DK; Hirbe AC
Neuro Oncol; 2023 Nov; 25(11):2044-2057. PubMed ID: 37246765
[TBL] [Abstract][Full Text] [Related]
2. Chromosome 8 gain is associated with high-grade transformation in MPNST.
Dehner C; Moon CI; Zhang X; Zhou Z; Miller C; Xu H; Wan X; Yang K; Mashl J; Gosline SJ; Wang Y; Zhang X; Godec A; Jones PA; Dahiya S; Bhatia H; Primeau T; Li S; Pollard K; Rodriguez FJ; Ding L; Pratilas CA; Shern JF; Hirbe AC
JCI Insight; 2021 Mar; 6(6):. PubMed ID: 33591953
[TBL] [Abstract][Full Text] [Related]
3. A High-Throughput Screening Platform Identifies Novel Combination Treatments for Malignant Peripheral Nerve Sheath Tumors.
Fernández-Rodríguez J; Creus-Bachiller E; Zhang X; Martínez-Iniesta M; Ortega-Bertran S; Guha R; Thomas CJ; Wallace MR; Romagosa C; Salazar-Huayna L; Reilly KM; Blakely JO; Serra-Musach J; Pujana MA; Serra E; Villanueva A; Ferrer M; Lázaro C
Mol Cancer Ther; 2022 Jul; 21(7):1246-1258. PubMed ID: 35511749
[TBL] [Abstract][Full Text] [Related]
4. Patterns of recurrence and survival in sporadic, neurofibromatosis Type 1-associated, and radiation-associated malignant peripheral nerve sheath tumors.
Watson KL; Al Sannaa GA; Kivlin CM; Ingram DR; Landers SM; Roland CL; Cormier JN; Hunt KK; Feig BW; Ashleigh Guadagnolo B; Bishop AJ; Wang WL; Slopis JM; McCutcheon IE; Lazar AJ; Torres KE
J Neurosurg; 2017 Jan; 126(1):319-329. PubMed ID: 27035165
[TBL] [Abstract][Full Text] [Related]
5. MEK Inhibition Synergizes with TYK2 Inhibitors in NF1-Associated Malignant Peripheral Nerve Sheath Tumors.
Borcherding DC; Amin NV; He K; Zhang X; Lyu Y; Dehner C; Bhatia H; Gothra A; Daud L; Ruminski P; Pratilas CA; Pollard K; Sundby T; Widemann BC; Hirbe AC
Clin Cancer Res; 2023 Apr; 29(8):1592-1604. PubMed ID: 36799629
[TBL] [Abstract][Full Text] [Related]
6. Expanding a precision medicine platform for malignant peripheral nerve sheath tumors: New patient-derived orthotopic xenografts, cell lines and tumor entities.
Creus-Bachiller E; Fernández-Rodríguez J; Magallón-Lorenz M; Ortega-Bertran S; Navas-Rutete S; Romagosa C; Silva TM; Pané M; Estival A; Perez Sidelnikova D; Morell M; Mazuelas H; Carrió M; Lausová T; Reuss D; Gel B; Villanueva A; Serra E; Lázaro C
Mol Oncol; 2024 Apr; 18(4):895-917. PubMed ID: 37798904
[TBL] [Abstract][Full Text] [Related]
7. Clinical genomic profiling identifies TYK2 mutation and overexpression in patients with neurofibromatosis type 1-associated malignant peripheral nerve sheath tumors.
Hirbe AC; Kaushal M; Sharma MK; Dahiya S; Pekmezci M; Perry A; Gutmann DH
Cancer; 2017 Apr; 123(7):1194-1201. PubMed ID: 27875628
[TBL] [Abstract][Full Text] [Related]
8. From Genes to -Omics: The Evolving Molecular Landscape of Malignant Peripheral Nerve Sheath Tumor.
Lemberg KM; Wang J; Pratilas CA
Genes (Basel); 2020 Jun; 11(6):. PubMed ID: 32599735
[TBL] [Abstract][Full Text] [Related]
9. Molecular characterization of permanent cell lines from primary, metastatic and recurrent malignant peripheral nerve sheath tumors (MPNST) with underlying neurofibromatosis-1.
Fang Y; Elahi A; Denley RC; Rao PH; Brennan MF; Jhanwar SC
Anticancer Res; 2009 Apr; 29(4):1255-62. PubMed ID: 19414372
[TBL] [Abstract][Full Text] [Related]
10. Chromosomal translocations inactivating CDKN2A support a single path for malignant peripheral nerve sheath tumor initiation.
Magallón-Lorenz M; Fernández-Rodríguez J; Terribas E; Creus-Batchiller E; Romagosa C; Estival A; Perez Sidelnikova D; Salvador H; Villanueva A; Blanco I; Carrió M; Lázaro C; Serra E; Gel B
Hum Genet; 2021 Aug; 140(8):1241-1252. PubMed ID: 34059954
[TBL] [Abstract][Full Text] [Related]
11. Molecular evolution of a neurofibroma to malignant peripheral nerve sheath tumor (MPNST) in an NF1 patient: correlation between histopathological, clinical and molecular findings.
Spurlock G; Knight SJ; Thomas N; Kiehl TR; Guha A; Upadhyaya M
J Cancer Res Clin Oncol; 2010 Dec; 136(12):1869-80. PubMed ID: 20229272
[TBL] [Abstract][Full Text] [Related]
12. Beyond "Triton": Malignant Peripheral Nerve Sheath Tumors With Complete Heterologous Rhabdomyoblastic Differentiation Mimicking Spindle Cell Rhabdomyosarcoma.
Hornick JL; Nielsen GP
Am J Surg Pathol; 2019 Oct; 43(10):1323-1330. PubMed ID: 31107719
[TBL] [Abstract][Full Text] [Related]
13. Malignant peripheral nerve sheath tumor in children: A clinicopathologic and molecular study with parallels to the adult counterpart.
Agaram NP; Wexler LH; Chi P; Antonescu CR
Genes Chromosomes Cancer; 2023 Mar; 62(3):131-138. PubMed ID: 36414547
[TBL] [Abstract][Full Text] [Related]
14. Detection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis using aneuploidy and mutation identification in plasma.
Mattox AK; Douville C; Silliman N; Ptak J; Dobbyn L; Schaefer J; Popoli M; Blair C; Judge K; Pollard K; Pratilas C; Blakeley J; Rodriguez F; Papadopoulos N; Belzberg A; Bettegowda C
Elife; 2022 Mar; 11():. PubMed ID: 35244537
[TBL] [Abstract][Full Text] [Related]
15. RRM2 as a novel prognostic and therapeutic target of NF1-associated MPNST.
Chung MH; Aimaier R; Yu Q; Li H; Li Y; Wei C; Gu Y; Wang W; Guo Z; Long M; Li Q; Wang Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1399-1413. PubMed ID: 37086345
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of magnetic resonance imaging-based radiomics characteristics for differentiation of benign and malignant peripheral nerve sheath tumors in neurofibromatosis type 1.
Ristow I; Madesta F; Well L; Shenas F; Wright F; Molwitz I; Farschtschi S; Bannas P; Adam G; Mautner VF; Werner R; Salamon J
Neuro Oncol; 2022 Oct; 24(10):1790-1798. PubMed ID: 35426432
[TBL] [Abstract][Full Text] [Related]
17. Confirmation of mutation landscape of NF1-associated malignant peripheral nerve sheath tumors.
Sohier P; Luscan A; Lloyd A; Ashelford K; Laurendeau I; Briand-Suleau A; Vidaud D; Ortonne N; Pasmant E; Upadhyaya M
Genes Chromosomes Cancer; 2017 May; 56(5):421-426. PubMed ID: 28124441
[TBL] [Abstract][Full Text] [Related]
18. [Malignant peripheral nerve sheath tumor: a clinicopathological analysis].
Peng W; Gong QX; Fan QH; Liu Y; Song GX; Wei YZ
Zhonghua Bing Li Xue Za Zhi; 2023 Sep; 52(9):924-930. PubMed ID: 37670622
[No Abstract] [Full Text] [Related]
19. Low mutation burden and frequent loss of CDKN2A/B and SMARCA2, but not PRC2, define premalignant neurofibromatosis type 1-associated atypical neurofibromas.
Pemov A; Hansen NF; Sindiri S; Patidar R; Higham CS; Dombi E; Miettinen MM; Fetsch P; Brems H; Chandrasekharappa SC; Jones K; Zhu B; Wei JS; ; ; Mullikin JC; Wallace MR; Khan J; Legius E; Widemann BC; Stewart DR
Neuro Oncol; 2019 Aug; 21(8):981-992. PubMed ID: 30722027
[TBL] [Abstract][Full Text] [Related]
20. WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth.
Thomson CS; Pundavela J; Perrino MR; Coover RA; Choi K; Chaney KE; Rizvi TA; Largaespada DA; Ratner N
Oncogene; 2021 Jun; 40(24):4229-4241. PubMed ID: 34079083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]